NEW YORK (GenomeWeb) — Pacific Biosciences announced this week that it has reached the final developmental milestone of its commercialization and licensing agreement with Roche. The agreement, originally announced in September, entitles Roche to commercialize and sell clinical diagnostics products developed by PacBio based on the company's Single Molecule, Real Time technology. With the final milestone achieved, Roche has paid PacBio an additional $20 million.